The primary objective of this study is to compare the bioavailability of new oral formulation(s) of moxidectin with the bioavailability of moxidectin tablets, 2mg. Adult volunteers will take a single dose of moxidectin 8 mg as either (4 x 2 mg) tablets or as an alternative oral formulation suitable for administration to children. Blood samples will be taken from each participant at pre-specified intervals after dosing for determination of moxidectin blood levels. The range of exposures (concentration of moxidectin in blood over time) in each treatment group will be compared to determine whether the new formulation(s) deliver the same amount of drug as the tablets and are therefore bioequivalent.
|Effective start/end date||1/01/21 → 30/07/25|
- European and Developing Countries Clinical Trials Partnership (EDCTP): €2,112,690.50
- FNR - Fonds National de la Recherche: €724,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.